The effect of an incentive billing code on heart failure management in primary care: a population-based study

Abstract

Background To support family physicians (FPs) in managing patients with heart failure (HF), the Ministry of Health in Ontario, Canada, implemented the Q050 billing code in 2008, a pay-for-performance (P4P) incentive for guideline-based HF care. We studied whether the incentive was associated with any change in process-of-care measure, particularly the prescriptions of HF medications.

Methods We identified all patients with HF in Ontario of age≥66, who were managed by FPs claiming the Q050 incentive between 2008 and 2021. We counted the number of patients who were prescribed renin-angiotensin system inhibitors (RASi), beta-blockers (BB), mineralocorticoid receptor antagonists (MRA), and diuretics three months before and after the Q050 billing code was claimed for these patients. Where applicable, we classified the agents within each class by whether they are guideline-directed as recommended by the Canadian Cardiovascular Society (CCS).

Results We included 39,425 HF patients in the study. The median age was 80 (IQR 73-85) years; 49% were female. Half were assessed by an internist or cardiologist during the six months before their HF diagnosis. Compared to pre-Q050, there was an increase in RASi prescriptions from 42.5% to 45.8%, BB from 51.9% to 54.4%, MRA from 9.2% to 11.7%, and diuretics from 63.2% to 65.7% after the incentive (p<0.05). There was a decrease in those not on any HF medications from 27.5% to 24.9% (p<0.001). Those with newly diagnosed HF and prompt follow-up with FPs experienced the largest but clinically modest increase in HF medications.

Conclusions To our knowledge, this is the first evaluation of process-of-care measures related to a pay-for-performance program in primary care HF management. The Q050 incentive led to a minimal increase in the prescription of HF medications; there is underutilization of disease-modifying agents. Further research is needed to understand why pay-for-performance programs had no effect on physician prescribing behaviours.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was funded by grants from Physicians Services Incorporated (PSI) and a Foundation grant from the Canadian Institutes of Health Research (CIHR grant # FDN 148446). Dr. Lee is supported by the Ted Rogers Chair in Heart Function Outcomes, University Health Network, University of Toronto.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Hamilton integrated Research Ethics Board

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

The datasets from this study are held securely in coded form at the ICES. Although legal data?sharing agreements prohibit ICES from making the data set publicly available, access may be granted to those who meet prespecified criteria for confidential access, available at https://www.ices.on.ca/DAS (email: das@ices.on.ca). The full dataset creation plan and underlying analytic code are available from the authors upon request, understanding that the computer programs may rely on coding templates or macros that are unique to ICES and are, therefore, inaccessible or may require modification.

留言 (0)

沒有登入
gif